Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head-to-Head Randomized Phase IIIb Study,Arthritis & Rheumatology

当前位置： X-MOL 学术 › Arthritis Rheumatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head-to-Head Randomized Phase IIIb Study
Arthritis & Rheumatology ( IF 13.3 ) Pub Date : 2024-03-31 , DOI: 10.1002/art.42852
Xenofon Baraliakos ₁ , Mikkel Østergaard _{2,

3} , Denis Poddubnyy ₄ , Désirée van der Heijde ₅ , Atul Deodhar ₆ , Pedro M. Machado ₇ , Victoria Navarro‐Compán ₈ , Kay Geert A. Hermann ₉ , Mitsumasa Kishimoto ₁₀ , Eun Young Lee ₁₁ , Lianne S. Gensler ₁₂ , Uta Kiltz ₁ , Marco F. Eigenmann ₁₃ , Patricia Pertel ₁₃ , Aimee Readie ₁₄ , Hanno B. Richards ₁₃ , Brian Porter ₁₄ , Juergen Braun ₁₅

Affiliation

Ruhr‐University Bochum, Bochum, Rheumazentrum Ruhrgebiet Herne Germany
Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Center of Head and Orthopedics, Rigshospitalet Glostrup Denmark
Department of Clinical Medicine University of Copenhagen Copenhagen Denmark
Charité Universitätsmedizin Berlin and German Rheumatism Research Centre Berlin Germany
Leiden University Medical Center Leiden The Netherlands
Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University Portland USA
Department of Neuromuscular Diseases & Centre for Rheumatology University College London London UK
Department of Rheumatology La Paz University Hospital, IdiPaz Madrid Spain
Charité Universitätsmedizin Berlin, Department of Radiology, Charitéplatz 1 Berlin Germany
Department of Nephrology and Rheumatology Kyorin University School of Medicine Tokyo Japan
Division of Rheumatology Department of Internal Medicine Seoul National University College of Medicine Seoul South Korea
Department of Medicine/Rheumatology University of California, San Francisco San Francisco CA USA
Novartis Pharma AG Basel Switzerland
Novartis Pharmaceuticals Corporation East Hanover New Jersey USA
Rheuma Praxis Berlin, and Ruhr‐Universitäty Bochum Germany

Spinal radiographic progression is an important outcome in radiographic axial spondyloarthritis (SpA). The objective of the phase IIIb SURPASS study was to compare spinal radiographic progression in patients with radiographic axial SpA treated with secukinumab (interleukin-17A inhibitor) versus adalimumab biosimilar (Sandoz adalimumab [SDZ-ADL]; tumor necrosis factor inhibitor).

中文翻译：

Secukinumab 与阿达木单抗生物类似药对放射学中轴型脊柱关节炎患者放射学进展的影响：头对头随机 IIIb 期研究的结果

脊柱放射学进展是放射学中轴型脊柱关节炎 (SpA) 的一个重要结果。 IIIb 期 SURPASS 研究的目的是比较接受苏金单抗（白细胞介素 17A 抑制剂）与阿达木单抗生物仿制药（山德士阿达木单抗 [SDZ-ADL]；肿瘤坏死因子抑制剂）治疗的放射学轴性 SpA 患者的脊柱放射学进展。

更新日期：2024-03-31

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>